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Abstract
Introduction. Obstructive sleep apnea (OSA) is one of the most common sleep disorders, which affects 4% of men and 
2% of women in the world population. The disorder can be diagnosed in men and women of all ages; however, its inci-
dence increases with age. Patients with OSA experience increased levels of sympathetic nervous system activity, which 
is evidenced by the increased catecholamines secretion. They are at an increased risk of developing complications of 
coronary heart disease (CHD).
The aim of the study was to evaluate the influence of results of screening for OSA on the activity of the sympathetic and 
parasympathetic nervous systems within the scope of selected heart rate variability (HRV) parameters (time-domain 
and frequency-domain analyses of the HRV) in patients with CHD.
Material and methods. Holter recordings of 146 patients aged 43–78 (106 of whom were men) were analysed retrospec-
tively. The patients were divided into four groups on the basis of the estimated apnea–hypopnea index (eAHI), assessed 
by means of 24-hour recordings of electrocardiogram with Lifescreen Apnea software: < 5 (control group), from 5 to < 15 
(mild), from 15 to < 30 (moderate) and ≥ 30 episodes (severe). For each patient, a profile of power spectrum alterations 
was developed for low frequency (LF) and high frequency (HF) in 60-minute periods between 10 p.m. and 6 a.m. and stan-
dard deviation of RR intervals (SDNN) and root mean square of successive differences (rMSSD) values were calculated. 
The power spectrum in the consecutive one-hour periods was averaged in both groups. In view of the right-skewed distri-
bution of data, the average power spectra were converted into natural logarithms. In order to assess the significance of 
variations, the natural logarithms of the average values were compared using the univariate analysis of variance (ANOVA).
Results. In the examined groups, there were statistically significant differences in the HF band of power spectrum be-
tween the control group and the group of patients with mild OSA (p < 0.01), those with severe OSA (p < 0.01) and also 
between the group with mild and moderate OSA (p < 0.01). In the LF band of power spectrum, the only difference was 
seen between the group of patients with mild OSA and those with moderate OSA (p < 0.01). In the time-domain analysis 
of HRV (SDNN, rMSSD), no statistically significant differences between the groups were observed.
Conclusions. High frequency band of power spectrum [HF] in frequency-domain HRV analysis could be a more effective 
parameter to distinguish patients with mild OSA (from 5 to < 15) and severe OSA (≥ 30) in patients suffering from CHD, 
than the power spectrum for LF or SDNN and rMSSD.
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Introduction
Obstructive sleep apnea (OSA) is one of the most common 
sleep disorders present in about 4% of men and 2% of wo-
men [1, 2]. Recent study by Pappard et al. [3] indicates, that 
prevalence of sleep-disordered breathing tend to increase 
over the last two decades. OSA is the result of an excessive 
drop in the tension of the muscles of the soft palate, tongue 
and the back wall of the throat. Depending on the severity 
of this drop, the patient develops impairment (hypopnea) 
or a temporary blockage of the airflow (apnea) in the up-
per respiratory tract [4, 5]. The disease can be diagnosed 
regardless of age and sex, and its incidence increases with 
age [6]. Heart rate variability (HRV) is the cyclically repeated 
occurrence of differences in the time interval between two 
successive heartbeats in the electrocardiogram (ECG). He-
art rate variability is influenced by the interaction between 
the sympathetic and parasympathetic components of the 
autonomic nervous system, which undergo changes in cer-
tain morbid conditions. The measurements of time-domain 
and frequency-domain analyses of HRV are valuable and 
non-invasive methods of assessing the function of the 
autonomic regulation of the heart rate [7, 8].
During sleep, a person with OSA experiences rapid 
changes in the frequency of the sinus rhythm, with pe-
riods of deceleration of the rhythm (bradycardia) and 
parasympathetic predominance, which alternate with 
periods of rapidly increasing acceleration of the rhythm 
as a result of the stronger activity of the adrenergic 
system. Although the pathophysiological mechanism of 
OSA is not fully understood, it is assumed that repeated 
drops in oxygen saturation of arterial blood, an increased 
activity of the renin–angiotensin–aldosterone system and 
an increased activity of the sympathetic nervous system, 
with an increased secretion of catecholamines are risk 
factors for arterial hypertension [9], metabolic syndrome 
[10], and cardiac arrhythmias [11, 12]. There were already 
some attempts performed to find a relationship between 
severity of OSA and changes in HRV — nevertheless their 
limited value is caused by a small sample size [13, 14]. 
Since Holter ECG monitoring is recorded in every patient 
during cardiac rehabilitation programme, we decided to 
use our database in purpose to verify this relationship in 
a larger sample [15].
The aim of the study was to evaluate retrospectively 
the relationship between values of calculated index of OSA 
and the activity of the sympathetic and parasympathetic 
nervous systems as regards selected HRV parameters 
in patients with a coronary artery disease, with special 
reference to selected most frequently used time-domain 
parameters (the standard deviation of all RR intervals 
[SDNN]; the root mean square of the successive diffe-
rences between adjacent RRs [rMSSD]) and frequency-
-domain parameters (low frequency [LF] power spectrum 
[0,04–0,15 Hz]; high frequency [HF] power spectrum 
[0,15–0,4 Hz]). The assumption of this study was that the 
level of OSA severity in patients with a diagnosed coronary 
artery disease, can be associated with the differences in 
degree of activity of the sympathetic nervous system in-
teracting with the activity of the parasympathetic system. 
The abovementioned calculated index of OSA — so called 
estimated apneahypopnea index (eAHI) is obtained from 
24-hour ECG Holter recordings and is used by cardiologists 
to refer cardiac patients with its highest values to perform 
polysomnography.
Material and methods
The study group
The Holter ECG recordings of 146 patients (106 men) aged 
43–78 with a coronary artery disease confirmed by means 
of coronary catheterisation were analysed retrospectively. 
The Holter recordings of patients qualified for the study 
were chosen from the archive of data of those who were 
hospitalised in the Department of Cardiology because 
of an acute coronary syndrome (ST-elevation myocardial 
infarction, non ST-elevation myocardial infarction or un-
stable angina), and who were later — in the second stage 
of cardiac rehabilitation — patients of the Department of 
Cardiac Rehabilitation in the same hospital. The patients 
begun cardiac rehabilitation programme within 30 days 
after being discharged from hospital. The inclusion criterion 
was sinus rhythm in the baseline ECG on the first day of the 
rehabilitation. We did not include patients with a history of 
paroxysmal atrial fibrillation, with an implanted device for 
electrotherapy, or with premature ventricular contractions 
present in the resting ECG, since these conditions might 
make impossible to analyse the Holter recordings for the 
purpose of this study. Patients with wearable cardioverter-
-defibrillator due to recent (less than 40 days after the 
event) myocardial infarction and subsequent low ejection 
fraction of left ventricle (≤ 35%) were excluded from this 
study. We excluded patients with anaemia, with thyroid 
dysfunction, and with clinical or laboratory features of 
inflammation, as having conditions with reversible impact 
on heart rate. Also patients with known diagnosis of sleep 
apnea, neuromuscular or skeletal disease affecting bre-
athing were excluded. The protocol of presented study was 
approved by the Local Ethics Commission. As retrospective 
study, performed using archived data, in this case signing 
informed consent by patients was not necessary.
All the patients underwent a 24-hour ECG Holter 
monitoring (Pathfinder 700, DelMar Reynolds, Hertford, 
UK) performed within last week of 24-day cardiac reha-
bilitation programme for out-patients. The patients were 
assigned to four groups on the basis of the estimated 
apnea–hypopnea index (eAHI — the predicted number of 
apnea or hypopnea episodes) calculated on the basis of 
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the 24-hour ECG Holter recordings evaluated by means of 
the Lifescreen Apnea software: < 5 episodes — the control 
group, from 5 to < 15 — mild sleep apnea, from 15 to < 30 
— moderate sleep apnea and ≥ 30 episodes — severe sleep 
apnea (Figure 1). The clinical characteristics of patients 
is presented in Table 1.
Material and methods
Twenty-four-hour ECG monitoring was performed using 
a three-channel recorder Lifecard CF. It was followed by 
a further analysis with the Pathfinder 700 software and 
evaluation of the estimated AHI with Lifescreen Apnea (Spa-
celabs Healthcare, Issaquah WA, USA). As it was mentioned, 
an apneic event triggers the autonomic nervous system 
activation, which results in a specific sinus heart rhythm 
modulation. Lifescreen Apnea is a screening tool, which 
calculates the probability of apneic events on the basis of 
changes in the beat-to-beat intervals and the ECG-derived 
respiration signal. A detailed description of the method 
was given by de Chazal et al. [16]. Thanks to the inclusion 
of the ECG-derived respiration signal into the diagnostic 
algorithm, it is possible to evaluate chest movements indi-
rectly. This method can be used to detect obstructive and 
mixed apnea. The probability of sleep apnea is calculated 
for consecutive one-minute intervals and then for longer 
intervals. When the probability is greater than 50%, the 
program assumes, that an event occurred. Similarly to the 
polysomnographic AHI, in this method the estimated AHI 
(eAHI) is calculated for the whole sleep period, and eAHI 
< 5 is regarded as normal, eAHI ≥ 5 but < 15 is considered 
as borderline, and eAHI ≥ 15 as sleep disordered breathing. 
The minimum required sleep length was six hours, and 
the hours of sleep were self-reported by the patients. The 
usefulness of this method was verified by comparison with 
polysomnography [17]. The HRV was assessed according 
to the guidelines of the European Society of Cardiology 
and the North American Society of Pacing and Electro-
physiology [18]. Time-domain analysis was performed from 
whole 24-Holter recordings and included SDNN and rMSSD. 
The frequency-domain analysis was performed with Fast 
Fourier Transform method and power spectrum of low- as 
well high-frequency were assessed. The power spectrum for 
both frequencies was expressed in ms2. Each hour of Holter 
recording was divided into 5-minute intervals. In order to 
measure the analysed parameters of spectral analysis 
of HRV from each hour, a 5-minute period from first four 
intervals with lowest percentage of exclusions was chosen. 
The following were eliminated from the analysis: the RR 
intervals which lasted > 2 s and < 300 ms and > 120% 
and < 80% of the last RR interval. The minimal percentage 
of the evolutions of rhythm qualified for the assessment 
of HRV was > 90%.
For each patient, the profile of power spectrum changes 
in the LF and HF bands in 60-minute intervals between 
10.00 p.m. to 6.00 a.m. next day was determined. LF/HF 
ratio was calculated for every individual and averaged in 
investigated subgroups.
Figure 1. Study flow chart; STEMI — ST-elevation myocardial infarction; NSTEMI — non-ST-elevation myocardial infarction; ECG — electro-
cardiogram; eAHI — estimated apnea–hypopnea index; SDNN — standard deviation of all RR intervals, rMSSD — root mean square of the 
successive differences between adjacent RRs; LF — low frequency; HF — high frequency
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Statistical methods
The results of the power spectrum measurements were 
averaged for successive 1-hour intervals in the four groups. 
Because of the rightward-skewed distribution of the mean 
values of the power spectrum, they were converted to na-
tural logarithms. In order to assess the significance of the 
differences, the natural logarithms of the mean values were 
compared, using one-way analysis of variance (ANOVA). In 
order to compare the groups of patients with respect to the 
severity of OSA in terms of risk factors of atherosclerosis, 
or the percentage of people taking beta-adrenolytics — 
a chi-square test was used. Results with p < 0.05 were 
considered to be statistically significant.
Results
Calculation of eAHI revealed, that 23 (15.7%) patients 
had high probability of severe sleep apnea (eAHI ≥ 30), 
52 patients (35.6%) — moderate (eAHI from 15 to < 30), 
49 (33.6%) — mild (eAHI — from 5 to < 15) and 22 (15.1%) 
could be included into control group, as their eAHI was 
below 5.
Patients after a myocardial infarction constituted 
85.6% of the investigated group, arterial hypertension was 
diagnosed in 78.7%; type 2 diabetes mellitus — in 26%; 
obesity (BMI > 30 kg/m2) — in 25.3%. In comparison with 
the control group, patients from the groups with mild and 
moderate OSA had obesity (BMI > 30 kg/m2) significantly 
more frequently (p < 0.05), and a higher percentage of 
a myocardial infarction. The percentage of men was the 
highest in the group with moderate OSA and was signifi-
cantly different from the percentage of men in the control 
group. There were no significant differences in any OSA 
category in comparison with the control group as regards 
type 2 diabetes mellitus, arterial hypertension or taking 
beta-adrenolytics. When patients with eAHI < 15 (controls 
and mild OSA) were compared with those having eAHI 
≥ 15, no significant differences were found in prevalence 
of male gender, BMI > 30, diabetes mellitus, history of 
myocardial infarction, arterial hypertension or treatment 
with beta-adrenolytics (Table 1).
The results of time-domain and frequency-domain 
analyses of HRV in patients with three categories of OSA 
(mild, moderate, and severe) and in the control group are 
presented in Table 2. Spectral power analysis showed 
that there were statistically significant differences in the 
HF band between the control group and the patients with 
mild OSA (p < 0.01) and severe OSA (p < 0.01). Spectral 
power analysis in the LF band did not show any statisti-
cally significant differences. Time-domain analysis of HRV 
(SDNN, rMSSD) did not show any statistically significant 
differences between the groups. Despite numerical trend 
showing increasing LF/HF ratio in dependence from eAHI 
value, only difference between LF/HF ratio in patients with 
severe OSA and controls reached statistical significance. 
Also when patients with eAHI < 15 (controls and mild 
OSA) were compared with those having eAHI ≥ 15 neither 
differences in SDNN, nor in rMSSD, LF, HF band or LF/HF 
values reached statistical significance (Table 2).
Discussion
First most important finding of our study was very high 
prevalence of OSA in patients treated due to acute coronary 
Table 1. Clinical features of patients with obstructive sleep apnea (OSA) and controls, as well as those with estimated apnea–hypopnea 
index (eAHI) < 15 (control and mild OSA) and ≥ 15 (moderate and severe OSA)
Clinical features Severe 
OSA
Moderate 
OSA
Mild OSA Control Mild OSA 
vs.  
control
Moderate 
OSA vs. 
control
Severe 
OSA vs. 
control
eAHI < 15 eAHI 
≥ 15
eAHI 
< 115 
vs. ≥ 15
Male n [%] 17 
[73.91]
43 
[82.69]
34 
[69.38]
12 
[54.54]
ns < 0.01 ns 46  
[64.7]
60 
[80.00]
ns
BMI > 30 n [%] 3  
[13.04]
16 
[30.77]
17 
[34.69]
1  
[4.45]
< 0.01 < 0.01 ns 18  
[25.4]
19  
[25.3]
ns
Diabetes melli-
tus type 2 n [%]
7  
[30.43]
16 
[30.77]
13 
[26.53]
2  
[9.09]
ns ns ns 15  
[21.1]
23  
[30.7]
ns
MI in history 
n [%]
20 
[86.95]
47 
[90.38]
44 
[89.79]
14 
[63.63]
< 0.01 < 0.01 ns 58  
[81.7]
67  
[89.3]
ns
Arterial hyper-
tension n [%]
21 
[91.30]
38 
[73.07]
39 
[79.59]
17 
[77.27]
ns ns ns 56  
[78.7]
59  
[78.7]
ns
Treatment with 
beta-adrenolytics 
n [%]
23  
[100]
49 
[94.23]
48 
[97.95]
20 
[90.90]
ns ns ns 68  
[95.5]
72  
[96.0]
ns
BMI — body mass index; MI — myocardial infarction; ns — not significant
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syndromes, with absence of self-reported sleepiness or 
presence of risk factors for sleep-disordered breathing. This 
observation is concordant with results of previous studies 
by Ben Ahmed [19] and Mehre [20].
Second most important result of this study is the fin-
ding, that severity of sleep apnea in patients with coronary 
artery disease can be correlated with power spectrum 
changes in the HF band, and that from the two methods 
of HRV analysis, only the frequency-domain analysis is 
helpful in identifying patients with breathing disturbances 
of the OSA type in this group.
The significant role of HRV analysis in the identification 
of patients with OSA, but without concomitant diseases 
was shown recently also by Gammoudi et al. [21]. Using 
polysomnography and 24-hour ECG Holter monitoring, the 
authors showed, on the basis of a relatively small group of 
patients, the strongest correlation between the severity of 
OSA (AHI from 5 to < 30 vs. ≥ 30) and the mean value of 
the RR interval. In contrast to those results, in a study of 
36 patients, Aydin et al. observed an increase in the power 
spectrum in the LF band, VLF band (very low frequency), 
and the ULF band (ultralow frequency) and a decrease in 
the power spectrum in the HF band in patients with OSA 
(both mild — AHI < 20 and severe — AHI > 20) in compa-
rison with the control group [22]. That group demonstra-
ted also a significantly lower rMSSD, which appeared in 
a comparison of the group with severe OSA and the control 
group, with emphasis on no cardiac history and no other 
diseases (arterial hypertension, heart failure, etc.) in the 
study group. Similar results and conclusions for patients 
with no previously diagnosed cardiovascular diseases, 
and who did not take any medication, were obtained by 
Narkiewicz et al. [23]. Additionally, Park et al. demonstra-
ted elegantly in 59 males with apnea–hyperpnea index 
> 17 and free from other diseases, that frequency domain 
indices tend to reveal the differences between patients 
with moderate and severe OSA better than time domain 
indices [24].
It must be emphasised, however, that an analysis 
of the activity of the autonomic system must take into 
account not only concomitant diseases (which have a big 
influence on the autonomic activity), especially arterial 
hypertension, heart failure [25] and diabetes mellitus 
[26], the type of medication taken by the patient, but 
even their gender and age [27]. In comparison with the 
patients discussed by the above-mentioned researchers, 
our patients did not have a previously diagnosed OSA, nor 
were they free from atherosclerosis risk factors and from 
medication which affected the heart rate and sleep ap-
nea, namely beta-adrenolytics (Table 2). Our patients with 
mild and moderate OSA showed significant differences in 
comparison with the controls with regard to the frequency 
of a history of a myocardial infarction and obesity. Palma 
et al. in a group of 30 patients with OSA with moderate 
and severe OSA and mean BMI > 31 kg/m2 demonstra-
ted that both acute and long-term continuous positive 
airway pressure reduces the sympathovagal imbalance 
by decrease LF modulation and increase HF modulation 
[28]. It is worth quoting here the results of a pilot study, 
which demonstrated that bariatric surgery had better 
effects on the improvement of HRV parameters in people 
with obesity and OSA than the use of continuous positive 
airway pressure treatment in this group of patients [29]. 
In our study, the frequency of type 2 diabetes mellitus did 
not differ significantly between the groups (p < 0.05) nor 
did that of arterial hypertension and the percentage of 
patients who took beta-adrenolytics. The repeated drops in 
arterial blood saturation and the increased activity of the 
renin–angiotensin–aldosterone system and the increased 
activity of the sympathetic system could be the potential 
Table 2. Comparison of HRV parameter in patients with obstructive sleep apnea (OSA) and controls, as well as those with estimated ap-
nea–hypopnea index (eAHI) < 15 (control and mild OSA) and ≥ 15 (moderate and severe OSA)
HRV para-
meter
Mild OSA Moderate 
OSA
Severe OSA Control Mild OSA 
vs. control
Moderate 
OSA vs. 
control
Severe 
OSA vs. 
control
eAHI < 15 eAHI ≥ 15 eAHI < 15  
vs. ≥ 15
SDNN 
[ms]
127,29  
± 32,77
123,63  
± 28,50
126.69  
± 32.82
127.10  
± 33.90
ns ns ns 127.23  
± 33.12
124.57  
± 29.82
ns
rMSSD 
[ms]
24.35  
± 9.51
26.35  
± 10.55
24.94  
± 9.31
24.55  
± 11.06
ns ns ns 24.41  
± 9.99
25.91  
± 10.16
ns
LF [ms2] 588.74  
± 590.97
675.76  
± 899.20
697.16  
± 976.58
358.45  
± 494.19
ns ns ns 517.37  
± 560.95
682.29  
± 922.93
ns
HF [ms2] 259.49  
± 320.53
289.55  
± 347.30
306.36  
± 366.07
267.42  
± 343.65
< 0.01 ns < 0.01 261.82  
± 327.13
294.21  
± 352.83
ns
LF/HF 1.15  
± 0.68
1.77  
± 0.74
2.1 ± 1.53 2.32  
± 1.88
ns ns < 0.05 1.51  
± 1.05
1.87  
± 0.98
ns
HRV — heart rate variability; ns — not significant; SDNN — standard deviation of all RR intervals, rMSSD — root mean square of the successive differences between adjacent RRs; LF — low frequency; HF — 
high frequency
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pathophysiological mechanism of the development of 
arterial hypertension, which appeared in most of our 
patients (Table 2) [30]. It is worth noting, that almost all 
our patients took beta-adrenolytics (100% of patients with 
severe OSA). It is a controversial issue whether this group 
of medicines should be used for the treatment of arterial 
hypertension and coronary artery disease in patients with 
OSA. Taking into account the mechanism of OSA, we must 
note, however, that the final phase of apnea is associated 
with recurrent bradycardia, and beta-adrenolytics have the 
potential to exacerbate this dangerous effect because of 
its negative chronotropic effect [31]. It has been shown, 
that around 52% of patients with heart failure who take 
beta-adrenolytics on a regular basis have OSA (AHI > 15) 
[32]. Additionally, recent study by Wolf et al. in hypertensive 
patients with OSA revealed that beta-adrenolytics attenu-
ate apnea-induced heart rate acceleration [33].
Another disputable issue is the usefulness and accu-
racy of the Holter diagnostics of sleep apnea. A reference 
polysomnographic examination is a costly procedure, time-
-consuming and less available, and therefore it cannot be 
used as a screening test. Recent publication confirms the 
reliability of a simpler diagnosis of obstructive respiratory 
disorders on the basis of 24-hour Holter monitoring by me-
ans of the Lifescreen Apnea software using eAHI in various 
groups of patients for screening purposes. This method 
is especially reliable with eAHI > 18 [17]. The identical 
method was used in our study. One study confirms the 
repeatability of the results from two consecutive nights on 
the basis of 48-hour ECG Holter monitoring [34]. Electro-
cardiographic techniques are also proposed to be used for 
monitoring of OSA [35]. An example of how cardiologists 
use Holter monitoring to assess the influence of sleeping 
pills on the possible aggravation of sleep apnea can be the 
publication describing the lack of significant changes in 
the eAHI in patients taking melatonin [36]. Nevertheless, it 
has to be emphasised, that Palma et al. recently reported 
that also sleep-related alveolar hypoventilation presents 
similar abnormalities in autonomic tone as observed in 
OSA [37]. This observation supports the importance of 
nocturnal hypoxia in inducing night-time abnormalities in 
frequency-domain indices, since the same author reported 
that patients with OSA, but without hypoxia, exhibit lower 
LF oscillations when compared with patients with OSA 
and hypoxia [38].
Conclusions
Our up-to-date largest study focused on relationship be-
tween HRV and OSA, suggests that when 24-hour ECG 
Holter monitoring can be used as screening for OSA, high 
frequency power spectrum in frequency-domain heart rate 
variability analysis can offer better parameters for the 
discrimination of coronary disease patients with mild OSA 
(from 5 to < 15) and with severe OSA (≥ 30) as compared 
to power spectrum in the LF band or time domain indices, 
such as SDNN and rMSSD.
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Streszczenie
Obturacyjny bezdech senny (OSA) jest jednym z najczęstszych zaburzeń snu, obecnym u około 4% mężczyzn i 2% kobiet. 
Choroba może być rozpoznawana niezależnie od wieku i płci; jej częstość wzrasta z wiekiem. U chorych z OSA w trakcie 
snu dochodzi do wzmożonej aktywności układu współczulnego i zwiększonego wówczas wydzielania amin katecholo-
wych. Pacjentów z OSA cechuje zwiększone ryzyko choroby wieńcowej (CHD).
Celem badania była ocena wpływu OSA na aktywność układów para- i sympatycznego w zakresie wybranych parame-
trów zmienności rytmu serca (HRV) — analizy czasowej i częstotliwościowej u chorych na CHD oraz przydatności tych 
parametrów w ustaleniu prawdopodobieństwa występowania bezdechów w czasie snu.
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Materiał i metody. Obserwacji retrospektywnej poddano 146 pacjentów w wieku 43–78 lat (106 mężczyzn) z CHD. 
Chorych przydzielono do 4 grup na podstawie szacowanego wskaźnika bezdechów–spłyconych oddechów (eAHI) uzy-
skanego na podstawie 24-godzinnego zapisu elektrokardiograficznego metodą Holtera za pomocą oprogramowania 
Lifescreen: wynik poniżej 5 (grupa kontrolna), od 5 do mniej niż 15 (łagodny OSA); od 15 do mniej niż 30 (umiarkowany 
OSA) oraz ponad 30 (ciężki OSA). Dla każdego pacjenta opracowano profil zmian mocy widma dla niskiej częstotliwości 
(LF) i mocy widma dla wysokiej częstotliwości (HF) w 60-minutowych przedziałach czasu od godziny 22:00 do 06:00, 
a także obliczono wartości odchylenia standardowego wszystkich normalnych odstępów NN (SDNN) i pierwiastka śred-
niej sumy kwadratów różnic miedzy sąsiadującymi odstępami NN (rMSSD) u poszczególnych pacjentów. Moc widma 
w kolejnych przedziałach godzinowych uśredniono w obu grupach. Ze względu na prawoskośny rozkład wartości średnie 
mocy widma przekodowano na logarytmy naturalne. W celu oceny istotności różnic porównano logarytmy naturalne ich 
średnich, wykorzystując jednoczynnikową analizę wariancji (ANOVA).
Wyniki. W badanych grupach wykazano istotne statystycznie różnice mocy widma w zakresie HF między grupą kontrolną 
a grupą pacjentów z łagodnym OSA (p < 0,01) oraz ciężkim OSA (p < 0,01), a także porównując grupy badanych z łagod-
nym i umiarkowanym OSA (p < 0,01.) Analizując moc widma w zakresie LF nie zaobserwowano istotnych statystycznie 
różnic oprócz porównania grup pacjentów z łagodnym i umiarkowanym OSA (p < 0,01). W analizie czasowej HRV (SDNN, 
rMSSD) nie wykazano istotnych statystycznie różnic między grupami.
Wnioski. Podsumowując, moc widma w zakresie HF analizy częstotliwościowej HRV może być lepszym parametrem do 
wyodrębnienia grupy chorych z OSA łagodnym (od 5 do < 15) i ciężkim (≥ 30) u pacjentów z CHD niż moc widma w za-
kresie LF lub SDNN i rMSSD.
Słowa kluczowe: obturacyjny bezdech senny, dysfunkcja układu autonomicznego, zmienność rytmu serca
Folia Cardiologica 2018; 13, 2: 114–121
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